GSK-2140944

CAS No. 1075236-89-3

GSK-2140944( Gepotidacin | GSK2140944 )

Catalog No. M10308 CAS No. 1075236-89-3

GSK-2140944 (Gepotidacin) is a novel potent, selective bacterial type II topoisomerase inhibitor in development for the treatment of conventional and biothreat pathogens.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 328 Get Quote
50MG 1746 Get Quote
100MG 2502 Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    GSK-2140944
  • Note
    Research use only, not for human use.
  • Brief Description
    GSK-2140944 (Gepotidacin) is a novel potent, selective bacterial type II topoisomerase inhibitor in development for the treatment of conventional and biothreat pathogens.
  • Description
    GSK-2140944 (Gepotidacin) is a novel potent, selective bacterial type II topoisomerase inhibitor in development for the treatment of conventional and biothreat pathogens, including Gram-positive pathogens and MRSA; shows antibacterial activity against MSSA and MRSA isolates (MIC90=0.5 ug/ml).Bacterial Infection Phase 2 Clinical.
  • In Vitro
    Gepotidacin is a novel, first-in-class, triazaacenaphthylene antibacterial that inhibits bacterial DNA gyrase and topoisomerase IV via a unique mechanism and has demonstrated in vitro activity against gram-negative and gram-positive bacterias , including drug-resistant strains, and also targets pathogens associated with other conventional and biothreat infections. The MIC50 and MIC90 for gepotidacin against the 25 N. gonorrhoeae isolates tested are 0.12 and 0.25 μg/mL, respectively. The gepotidacin MIC90s are as follows (in μg/mL): Streptococcus pyogenes, 0.25; Escherichia coli, 2; Moraxella catarrhalis, ≤0.06; Streptococcus pneumoniae, 0.25; Haemophilus influenzae, 1; Clostridium perfringens, 0.5; and Shigella spp., Gepotidacin hasin vitroactivity against causative pathogens of acute bacterial skin and skin structure infections (ABSSSIs).
  • In Vivo
    GSK2140944 MICs are 0.125 to 0.5 mg/L against the six MRSA isolates. ELF penetration ratios range from 1.1 to 1.4. Observed maximal decreases are 1.1 to 3.1 log10 CFU in neutropenic mice. The mean fAUC/MIC ratios required for stasis and 1-log-unit decreases are 59.3 ± 34.6 and 148.4 ± 83.3, respectively.
  • Synonyms
    Gepotidacin | GSK2140944
  • Pathway
    GPCR/G Protein
  • Target
    Antibacterial
  • Recptor
    Antibacterial
  • Research Area
    Infection
  • Indication
    Bacterial Infection

Chemical Information

  • CAS Number
    1075236-89-3
  • Formula Weight
    448.527
  • Molecular Formula
    C24H28N6O3
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO : 7.14 mg/mL 15.92 mM
  • SMILES
    O=C(C=NC(C=C1)=C23)N3[C@H](CN4CCC(NCC(N=C5)=CC6=C5OCCC6)CC4)CN2C1=O
  • Chemical Name
    (2R)-2-[[4-[[(3,4-Dihydro-2H-pyrano[2,3-c]pyridin-6-yl)methyl]amino]-1-piperidinyl]methyl]-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthylene-3,8-dione

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Bax BD, et al. Nature. 2010 Aug 19;466(7309):935-40. 2. Biedenbach DJ, et al. Antimicrob Agents Chemother. 2016 Jan 4;60(3):1918-23. 3. So W, et al. Antimicrob Agents Chemother. 2015 Aug;59(8):4956-61. 4. Farrell DJ, et al. Antimicrob Agents Chemother. 2017 Feb 23;61(3). pii: e02047-16.
molnova catalog
related products
  • Nevadensin

    Nevadensin is a naturally occurring selective inhibitor of human carboxylesterase 1 (hCE1) with an IC50 of 2.64 μM.

  • Azathramycin

    A macrolide antibiotic that effectively inhibits tumor angiogenesis by suppressing VEGFR2-mediated signaling pathways in lung cancer.

  • Methicillin sodium

    Methicillin Sodium is the sodium salt form of methicillin a semisynthetic beta-lactam penicillin antibiotic with beta-lactamase resistant activity.